The development of triple-negative breast cancer is facilitated by activating mutations in FGFR2-S252W, which induce epithelial-mesenchymal transition through FGFR2-STAT3 signaling [51]. This evidence concerns the gene FGFR2 and triple-negative breast carcinoma.